Scientific misconduct

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 9, 2024

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)

Retrieved on: 
Thursday, March 7, 2024

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • ]”
    On this news, BioVie’s stock price fell $1.25, or 29.3%, to close at $3.01 per share on November 9, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines – BIVI

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and certain officers.

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Thursday, March 7, 2024

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, Amylyx, Sunnova, and DICK’S Sporting Goods and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 5, 2024

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • Then, on August 22, 2023, Dick’s Sporting Goods revealed that profitability for the second quarter of 2023 was significantly lower than previously represented.
  • Dick’s Sporting Goods also lowered its profitability guidance for the rest of fiscal year 2023.
  • For more information on the DICK’S Sporting Goods class action go to: https://bespc.com/cases/DKS

BioVie Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline.

Retrieved on: 
Monday, March 4, 2024

LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) investors that a lawsuit was filed on behalf of investors that purchased BioVie securities between August 5, 2021 through November 29, 2023, inclusive (the “Class Period”).

Key Points: 
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • BioVie, a clinical-stage biopharmaceutical company, focuses on developing drug therapies for neurological, neurodegenerative, and advanced liver diseases.
  • However, the complaint alleges that during the Class Period, BioVie made false and misleading statements about its operations and prospects.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)

Retrieved on: 
Friday, March 1, 2024

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • ]”
    On this news, BioVie’s stock price fell $1.25, or 29.3%, to close at $3.01 per share on November 9, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Friday, March 1, 2024

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points: 
  • Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
  • Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
  • These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
  • Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines – BIVI

Retrieved on: 
Monday, February 26, 2024

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and certain officers.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.